Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
Holding QTRX?
Track your performance easily
QTRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.50 - $29.70
Previous Close$11.75
Volume256.54K
Average Volume (3M)397.84K
Market Cap
$450.95M
Enterprise Value$193.67M
Total Cash (Recent Filing)$296.86M
Total Debt (Recent Filing)$39.58M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 04, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding38,379,033
10 Day Avg. Volume544,280
30 Day Avg. Volume397,839
Standard Deviation0.18
R-Squared0.16
Alpha-0.00785
Financial Highlights & Ratios
Price to Book (P/B)1.26
Price to Sales (P/S)3.32
Price to Cash Flow (P/CF)-21.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit2.79
Enterprise Value/Ebitda-4.02
Forecast
1Y Price Target
$22.25Price Target Upside89.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Quanterix News
PremiumCompany Announcements
Quanterix Faces Nasdaq Compliance Challenge, Aims for Transparency
PremiumCompany Announcements
Quanterix Reports Strong Growth and New InnovationsBulls Say, Bears Say
Bulls Say
Financial PerformanceQTRX beat revenue expectations in preliminary 3Q results while reiterating their $134-138M FY24 revenue guidance.
Product Launch And Market PositionThe launch of LucentAD Complete positions Quanterix in the competitive $9 billion Alzheimer's diagnostics market.
Strategic Growth And InvestmentQTRX is well-capitalized with approximately $300 million in cash to invest in enhancing its portfolio and pursuing the Alzheimer's Disease diagnostics market.
Bears Say
Financial PerformanceInstrument revenue was down 39% and placements remain depressed with only 13 in the quarter, below estimates and previous records.
Market And Industry ConditionsManagement cites industry weakness likely to persist, with constraints on capital spending from academic and discovery customers affecting the company.
Regulatory And Policy ImpactPreliminary Clinical Lab Fee Schedule determinations for new codes were worse than expected for neuro diagnostics, negatively impacting the outlook for tests like blood-based pTau-217.
---
Ownership Overview
6.82% Insiders
23.32% Mutual Funds
32.25% Other Institutional Investors
25.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $10.50 and its highest was $29.70 in the past 12 months.
What is Quanterix Corporation’s market cap?
Currently, no data Available
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Mar 04, 2025 which is in 99 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Nov 12, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.244 by $0.044.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -$0.23.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 38,379,032 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.244. Following the earnings report the stock price went down -18.26%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Among the largest hedge funds holding Quanterix Corporation’s share is Gilder Gagnon Howe & Co LLC.. It holds Quanterix Corporation’s shares valued at 6M.
---
Quanterix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.25 (89.36% Upside)
$22.25 (89.36% Upside)
Hedge Fund Trend
Decreased
By 564.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $624.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.38%
12-Months-Change
Fundamentals
Return on Equity
-11.48%
Trailing 12-Months
Asset Growth
-4.18%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corp. is a life sciences company, which develops ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its Single Molecule Array (Simoa) technology platform uses single molecule measurements to access previously undetectable proteins. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Lexington, MA.
---
QTRX Company Deck
---
QTRX Earnings Call
Q3 2024
0:00 / 0:00
---
QTRX Stock 12 Month Forecast
Average Price Target
$22.25
▲(89.36% Upside)
Technical Analysis
Best Analysts Covering QTRX
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-20.54%
reiterated a buy rating 12 days ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -20.54% per trade.
---